|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5348878A
(en)
|
1990-05-10 |
1994-09-20 |
Dana-Farber Cancer Institute |
Class I MHC-restricted T-T hybridomas, and a CD8-transfected BW5147, fusion partner therefor
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
BR9907691B1
(pt)
|
1998-02-05 |
2011-05-31 |
|
derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
|
|
ID26964A
(id)
|
1998-02-19 |
2001-02-22 |
Xcyte Therapies Inc |
Komposisi dan metode untuk pengaturan pengaktifan limfosit
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
DK1187629T3
(da)
|
1999-04-19 |
2005-01-17 |
Glaxosmithkline Biolog Sa |
Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7514537B2
(en)
*
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
FR2827302B1
(fr)
|
2001-07-13 |
2003-10-10 |
Genoway |
Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
EP1616016B1
(en)
|
2003-03-19 |
2012-11-14 |
Isogenis, Inc. |
Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
|
|
JP4733635B2
(ja)
|
2003-07-31 |
2011-07-27 |
イミューノメディクス、インコーポレイテッド |
抗ｃｄ１９抗体
|
|
EP1765846A4
(en)
|
2004-07-13 |
2010-02-17 |
Cell Genesys Inc |
AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
|
|
CA2574802A1
(en)
|
2004-07-20 |
2006-02-02 |
Isogenis, Inc. |
Specific inhibition of autoimmunity and diseases associated with autoantigens
|
|
US8435507B2
(en)
*
|
2004-08-19 |
2013-05-07 |
University Of Maryland |
Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
|
|
WO2010105298A1
(en)
|
2009-03-18 |
2010-09-23 |
Simon Barry |
Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof
|
|
EP2601521B1
(en)
|
2010-08-06 |
2018-05-02 |
Ludwig-Maximilians-Universität München |
Identification of t cell target antigens
|
|
RU2729401C2
(ru)
|
2012-10-02 |
2020-08-06 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы для иммунотерапии
|
|
EP2931893A1
(en)
|
2012-12-13 |
2015-10-21 |
Universität Leipzig |
T-cell modulation by exon skipping
|
|
MY170528A
(en)
*
|
2013-02-18 |
2019-08-09 |
Vegenics Pty Ltd |
Vegfr-3 ligand binding molecules and uses thereof
|
|
US9848587B2
(en)
*
|
2013-02-20 |
2017-12-26 |
Regeneron Pharmaceuticals, Inc. |
Humanized T cell co-receptor mice
|
|
EP3215521B1
(en)
|
2014-11-06 |
2025-10-08 |
University of Maryland, Baltimore |
Cd8 and t cell receptor variants and methods of using same in modulating immune cell responses
|
|
CN113698497A
(zh)
*
|
2014-12-05 |
2021-11-26 |
纪念斯隆-凯特琳癌症中心 |
靶向b-细胞成熟抗原的嵌合抗原受体及其用途
|
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
KR102929174B1
(ko)
|
2015-10-30 |
2026-02-20 |
더 리전츠 오브 더 유니버시티 오브 캘리포니아 |
줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법
|
|
CN109072194B
(zh)
|
2015-12-09 |
2022-12-27 |
纪念斯隆-凯特林癌症中心 |
免疫细胞组合物及其使用方法
|
|
US11661455B2
(en)
|
2016-02-05 |
2023-05-30 |
Orionis Biosciences BV |
Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
|
|
CN109071632B
(zh)
*
|
2016-02-05 |
2022-12-30 |
奥里尼斯生物科学私人有限公司 |
靶向性治疗剂及其用途
|
|
WO2018161064A1
(en)
*
|
2017-03-03 |
2018-09-07 |
F1 Oncology, Inc. |
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
KR102397771B1
(ko)
|
2016-09-23 |
2022-05-13 |
프레드 헛친슨 켄서 리서치 센터 |
부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
|
|
AU2018234830B2
(en)
|
2017-03-15 |
2023-03-02 |
Fred Hutchinson Cancer Center |
High affinity MAGE-A1-specific TCRs and uses thereof
|
|
WO2019028295A1
(en)
*
|
2017-08-02 |
2019-02-07 |
La Jolla Institute For Allergy And Immunology |
COMPOSITIONS AND METHODS FOR ISOLATING AND / OR GENERATING SUB-ASSEMBLIES OF SPECIFIC CD4 + AND CD8 + T LYMPHOCYTES
|
|
AU2019256536C1
(en)
|
2018-04-19 |
2026-01-15 |
Baylor College Of Medicine |
Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors
|
|
US20210317184A1
(en)
|
2018-09-05 |
2021-10-14 |
GlaxoSmithKline Intellectual Property Devolopment Limited |
T cell modification
|
|
GB201819540D0
(en)
|
2018-11-30 |
2019-01-16 |
Adaptimmune Ltd |
T cell modification
|